半枝莲补肾合剂治疗中晚期非小细胞肺癌临床疗效研究

A clinical study on advanced NSCLC treated with the compound of scutellaria barbata kidney-tonifying

目的观察半枝莲补肾合剂治疗中晚期非小细胞肺癌(NSCLCⅢ～Ⅳ期)的临床疗效。方法治疗组50例中晚期非小细胞肺癌患者口服半枝莲右归饮合剂;对照组50例行NP方案化疗。结果治疗组0.5、1、2、3年生存率分别为86%、76%、72%、70%,对照组分别为92%、80%、68%、64%,两组比较差异无统计学意义(P>0.05)。3年期生活质量改善率治疗组为66%,对照组为36%(P<0.01)。近期疗效有效率治疗组为18%,对照组为60%(P<0.01);骨髓抑制率治疗组为6%,对照组为48%(P<0.01);细胞免疫功能CD4+/CD8+比值,治疗组为1.46±0.32,对照组为1.12±0.26(P<0.05);NK细胞活性治疗组为28.6±6.12,对照组为18.24±4.98(P<0.05)。结论半枝莲右归饮合剂治疗中晚期非小细胞肺癌与化疗方案比较,具有生活质量高、毒副反应低的优势。

Objective To investigate the clinical effect of scutellaria barbara kidney-tonifying compound on NSCLC stage Ⅲ - Ⅳ. Methods 50 cases in the trial group were treated with the compound of scutellaria barbata youguiyin, and 50 cases in the control group were treated with NP chemotherapy. Results The survival rate of 0. 5,1,2,3 years in the trial group were 86%, 76% ,72% and 70% respectively,while were 92% ,80% ,68% and 64% respectively in the control group,and the difference between the two groups was not significant （ P 〉 0. 05 ）. 3 years after treatment, the improve rate of life quality in the trial control was 66% ,and in the control group was 36% （P 〈0.01）. The late effect rate of tumor body in the trial group was 18% ,and in the control group was 60% （ P 〈 0. 01 ）. The inhibitive rate of marrow in the trial group was 6 % , and in the control group was 48% （P〈0.01）. The ratio of CD4^＋/CD8^＋ in the trial group was 1.46 ±0.32,and in the control group wasl. 12 ±0.26 （P〈 0.05 ）. The activity of NK cell in the trial group was 28. 6 ± 6. 12, and in the control group was 18.24 ± 4. 98 （P 〈 0. 05）. Conclusions Comparing to NP chemotherapy, the treatment of scutellaria barbata youguiyin compound has advantages on high life quality and low toxin side effect.